Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Single-arm, Open-label, Phase 4 Study to Evaluate the Safety and Efficacy of Brentuximab Vedotin Plus Doxorubicin, Vinblastine and Dacarbazine in Indian Patients With Untreated Stage 3/4 Classical Hodgkin Lymphoma

NCT06831370 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT06831370
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06831370 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Single-arm, Open-label, Phase 4 Study to Evaluate the Safety and Efficacy of Brentuximab Vedotin Plus Doxorubicin, Vinblastine and Dacarbazine in Indian Patients With Untreated Stage 3/4 Classical Hodgkin Lymphoma
Lead sponsor
Takeda
Phase
Phase 4
Overall status
Recruiting
Start date
August 28, 2024
Completion date
March 31, 2028
Enrollment
124 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin lymphoma